In the present study, using a large-scale health checkup and claims database including approximately 20,000 patients with MAFLD and DM, we compared the change in FLI between SGLT2 and DPP4 inhibitors after propensity score matching. The gene discussed is DPP4; the disease is diabetes mellitus.